How Ro rode the GLP-1 wave to a $7 billion telehealth valuation

Executive overview

Demand for GLP-1 weight loss drugs (Ozempic, Wegovy) exploded because they satisfy five criteria simultaneously: the majority of Americans are eligible, they are highly effective, scalable, wanted by patients, and supported by providers. Ro, a telehealth platform, pivoted early to obesity care and reached a $7 billion valuation by combining strategic timing with relentless operational responses to drug shortages.

The company's success came from a willingness to stop advertising, issue refunds, and make 40,000+ phone calls to pharmacies — prioritising existing patients over growth.

The core insight: treating obesity as a disease, not a willpower failure, unlocks a patient base of 110+ million eligible Americans.

The five reasons GLP-1 demand is unprecedented

• Majority of the US population (60–75%) is eligible
• Two to four times more effective than existing non-surgical options
• Scalable in a way that surgical interventions are not
• Patients actively want it
• Providers and healthcare systems broadly support access

How Ro responded to the 2023 shortage

• Stopped all advertising across TV, Facebook, Google, and out-of-home when Wegovy went on national shortage in May 2023
• Issued credits to every member unable to receive medication within 30 days
• Redirected all resources to locating supply: over 40,000–50,000 phone calls to pharmacies in July–August 2023
• Geo-matched available pharmacy stock to nearby patients, then transferred prescriptions
• Added Saxenda as an alternative (daily injection, lower efficacy but still superior to non-GLP-1 options)
• Resumed advertising in late November 2023 after Eli Lilly launched Zepbound

The 2022 refounding

• Consolidated multiple brands (Roman, Rory, Zero, Ro Derm) into a single Ro brand
• Cut approximately 20% of staff
• Shut down revenue-generating products to narrow focus
• Committed to obesity as the hero product ahead of market consensus

Why Ro targets stigmatised health categories

• ED, hair loss, and obesity share a common trait: patients need normalisation, not just treatment
• Ro's out-of-home obesity ads showed eligible-BMI patients in positions of power using the medication
• Ads generated controversy — but resonated directly with the patients who needed help
• Principle: speak to the people who need treatment; friction from others is acceptable

The cascading impact of GLP-1s

• Patients eat roughly 30% fewer calories; dietary preferences shift toward protein and vegetables
• Downstream effects expected across grocery, restaurant, travel, and healthcare industries
• GLP-1s are being studied for heart disease, chronic kidney disease, and sleep apnea
• Pipeline moving from weekly injectables toward monthly, semi-annual, and oral formulations
• Only a few million Americans currently use GLP-1s; 110+ million are eligible — growth has barely started

Cost and access outlook

• Uninsured patients pay ~$550/month; insured patients often pay under $100/month
• 30–40% of commercial employers and all federal employees currently cover GLP-1s
• Competition and pipeline expansion expected to drive prices down over time
• Oral formulations (daily or twice-daily tablets) will be easier and cheaper to scale than injectables